Article thumbnail

Nanoparticles and Colloids as Contributing Factors in Neurodegenerative Disease

By Stephen C. Bondy

Abstract

This review explores the processes underlying the deleterious effects of the presence of insoluble or colloidal depositions within the central nervous system. These materials are chemically unreactive and can have a prolonged residence in the brain. They can be composed of mineral or proteinaceous materials of intrinsic or exogenous origin. Such nanoparticulates and colloids are associated with a range of slow-progressing neurodegenerative states. The potential common basis of toxicity of these materials is discussed. A shared feature of these disorders involves the appearance of deleterious inflammatory changes in the CNS. This may be due to extended and ineffective immune responses. Another aspect is the presence of excess levels of reactive oxygen species within the brain. In addition with their induction by inflammatory events, these may be further heightened by the presence of redox active transition metals to the large surface area afforded by nanoparticles and amphipathic micelles

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:3138021
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A novel approach to the identification and quantitative elemental analysis of amyloid deposits-insights into the pathology of Alzheimer’s disease.
  2. (2005). Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q.
  3. (2010). Aging sensitizes rapidly isolated hippocampal microglia to LPS ex
  4. (2006). Aluminium and iron, but neither copper nor zinc, are key to the precipitation of β-sheets of Aβ42 in senile plaque cores in Alzheimer’s disease.
  5. (2006). Aluminum and copper in drinking water enhance inflammatory or oxidative events specifically in the brain.
  6. Amyloid associated proteins in Alzheimer’s and prion disease.
  7. (2011). Beta-sheet constitution of prion proteins.
  8. (2008). Changes in neurotransmitter levels and proinflammatory cytokine mRNA expressions in the mice olfactory bulb following nanoparticle exposure.
  9. (2008). Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci.
  10. (2009). Chelation therapy for neurodegenerative diseases.
  11. (2002). Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses.
  12. (2004). Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain.
  13. (2010). Comparative evaluation of the effects of short-term inhalation exposure to diesel engine exhaust on rat lung
  14. Copper-dependent functions for the prion protein.
  15. (2009). Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity.
  16. (2007). Effects of melatonin and age on gene expression in mouse CNS using microarray analysis.
  17. (2008). Enhanced formation of oxidants from bimetallic nickel-iron nanoparticles in the presence of oxygen.
  18. (2009). ER stress in Alzheimer’s disease: A novel neuronal trigger for inflammation and Alzheimer’s pathology.
  19. (2007). Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure.
  20. (2007). Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer’s disease.
  21. (2001). Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein.
  22. (1999). Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol. Aging
  23. (2008). Inhaled ultrafine particulate matter affects CNS inflammatory processes and may act via MAP kinase signaling pathways.
  24. (2010). Innate immunity and neuroinflammation in the CNS: The role of microglia in Toll-like receptor-mediated neuronal injury. Glia
  25. (2010). Ion channels in monocytes and microglia/brain macrophages: Promising therapeutic targets for neurological diseases.
  26. Mechanisms underlying aluminum-induced potentiation of oxidant properties of transition metals.
  27. (2010). Metalloproteomics and metal toxicology of α-synuclein. Metallomics
  28. Microglia and inflammation in Alzheimer’s disease.
  29. (2007). Microglial activation and its implications in the brain diseases.
  30. (2010). Microglial alterations in human Alzheimer’s disease following Ab42 immunisation.
  31. (2008). Microglial degeneration in the aging brain-bad news for neurons?
  32. (2010). Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation.
  33. (2006). Microglial senescence: Does the brain's immune system have an expiration date? Trends Neurosci.
  34. (2009). Mild steel welding fume causes manganese accumulation and subtle neuroinflammatory changes but not overt neuronal damage in discrete brain regions of rats after short-term inhalation exposure. Neurotoxicology
  35. Mitochondrial iron metabolism and its role in neurodegeneration.
  36. (2004). Mitochondrial-derived free radicals mediate asbestos-induced alveolar epithelial cell apoptosis.
  37. (2009). Nanoparticles and the brain: Cause for concern? Trends Neurosci.
  38. (2010). Nanoparticles induce changes of the electrical activity of neuronal networks on microelectrode array neurochips. Environ. Health Perspect.
  39. (2010). Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse. Neuroscience
  40. (2002). Neuroinflammation in Alzheimer’s disease and prion disease. Glia
  41. (2009). Neuroinflammation in prion diseases: Concepts and targets for therapeutic intervention. CNS Neurol. Disord. Drug Target.
  42. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy.
  43. (2009). Observation of beta-sheet aggregation in a gas-phase tau-peptide dimer.
  44. (2004). Oxidative basis of manganese neurotoxicity.
  45. (2005). Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology
  46. (2011). Particulate matter induced enhancement of inflammatory markers in the brains of apolipoprotein E knockout mice.
  47. (2006). Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington’s and Parkinson’s diseases.
  48. (2009). Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflamm. Allergy Drug Targets
  49. (2002). Pro-inflammatory effects of aluminum in human glioblastoma cells. Brain Res.
  50. (1998). Promotion of transition metal-induced production of reactive oxygen species formation by β-amyloid. Brain Res.
  51. (2009). Proteinopathy-induced neuronal senescence: A hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res. Ther.
  52. (2010). Risks of copper and iron toxicity during aging in humans.
  53. (2011). Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials.
  54. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells.
  55. (2008). Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant
  56. (2008). Stress proteins in CNS inflammation.
  57. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils.
  58. (2011). Surface-mediated production of hydroxyl radicals as a mechanism of iron oxide nanoparticle biotoxicity
  59. (2007). Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia
  60. (1991). Systemic macrophage stimulation in rats with silicosis: Enhanced release of tumor necrosis factor-alpha from alveolar and peritoneal macrophages.
  61. Targeting glial cells to elucidate the pathogenesis of Huntington’s disease.
  62. The chemistry of transition metals in relation to their potential role in neurodegenerative processes.
  63. (2005). The microglial “activation” continuum: From innate to adaptive responses.
  64. (2010). The neurotoxicity of environmental aluminum is still an issue. Neurotoxicology
  65. (1996). The promotion of iron-induced generation of reactive oxygen species in nerve tissue by aluminum.
  66. (2007). The redox chemistry of the Alzheimer’s disease amyloid beta peptide.
  67. (1999). The stabilization of ferrous iron by a toxic β-amyloid fragment and by an aluminum salt. Brain Res.
  68. (2008). Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles. Toxicology
  69. (2006). Translocation and potential neurological effects of fine and ultrafine particles a critical update. Par. Fibre Toxicol.
  70. (2007). Transport of intranasally instilled fine Fe2O3 particles into the brain: Micro-distribution, chemical states, and histopathological
  71. (2003). Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease.